Founders Fund V Management, LLC Cyclo Therapeutics, Inc. Transaction History
Founders Fund V Management, LLC
- $10.7 Billion
- Q3 2024
A detailed history of Founders Fund V Management, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Founders Fund V Management, LLC holds 480,708 shares of CYTH stock, worth $274,003. This represents 7.36% of its overall portfolio holdings.
Number of Shares
480,708
Previous 480,708
-0.0%
Holding current value
$274,003
Previous $610 Million
29.13%
% of portfolio
7.36%
Previous 72.16%
Shares
1 transactions
Others Institutions Holding CYTH
# of Institutions
20Shares Held
2.25MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA739KShares$421,4720.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$341,2550.0% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$86,8290.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$62,71318.16% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$33,9200.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $4.81M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...